PLEASANTON, Calif., Jan. 8, 2024
/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a
leader in single cell and spatial biology, today announced
preliminary, unaudited select results for the fourth quarter and
full year ended December 31,
2023.
Preliminary, Unaudited Select Fourth Quarter 2023 Financial
Results
- Revenue of approximately $184.0
million for the three months ended December 31, 2023, representing 18% growth over
the corresponding prior year period.
- Instruments revenue of approximately $38.4 million, representing 72% growth over the
corresponding prior year period. Instruments revenue consists of
approximately $11.1 million Chromium
instruments revenue and $27.2 million
Spatial instruments revenue.
- Consumables revenue of approximately $140.3 million, representing 7% growth over the
corresponding prior year period. Consumables revenue consists of
approximately $118.1 million Chromium
consumables revenue and $22.2 million
Spatial consumables revenue.
- Services revenue of approximately $5.3
million, representing 129% growth over the corresponding
prior year period.
Preliminary, Unaudited Select Full Year 2023 Financial
Results
- Revenue of approximately $618.7
million for the year ended December
31, 2023, representing 20% growth over the prior year.
- Instruments revenue of approximately $123.5 million, representing 71% growth over the
prior year. Instruments revenue consists of approximately
$47.9 million Chromium instruments
revenue and $75.6 million Spatial
instruments revenue.
- Consumables revenue of approximately $479.6 million, representing 10% growth over the
prior year. Consumables revenue consists of approximately
$420.3 million Chromium consumables
revenue and $59.2 million Spatial
consumables revenue.
- Services revenue of approximately $15.7
million, representing 86% growth over the prior year.
- Increased cumulative instruments sold to more than 5,900 as of
the end of 2023, which includes over 5,150 Chromium instruments,
over 500 Visium instruments and over 250 Xenium
instruments.
Preliminary Revenue Subject to Adjustment
10x
Genomics, Inc. has not completed preparation of its financial
statements for the fourth quarter or full year of 2023. The revenue
estimates presented in this news release for the quarter and year
ended December 31, 2023 are
preliminary and unaudited and are thus inherently uncertain and
subject to change as we complete preparation of our financial
statements for the fourth quarter and year ended December 31, 2023. 10x Genomics, Inc. is in the
process of completing its customary year-end close and review
procedures as of and for the quarter and year ended December 31, 2023, and there can be no assurance
that final results for these periods will not differ from these
estimates. During the course of the preparation of 10x Genomics,
Inc.'s consolidated financial statements and related notes as of
and for the year ended December 31,
2023, we or our independent registered public accountants
may identify items that could cause final reported results to be
materially different from the preliminary financial estimates
presented herein.
10x Genomics, Inc. plans to report final financial results for
the quarter and year ended December 31,
2023 in its February 2024
earnings call.
About 10x Genomics
10x Genomics is a life
science technology company building products to accelerate the
mastery of biology and advance human health. Our integrated
solutions include instruments, consumables and software for single
cell and spatial biology, which help academic and translational
researchers and biopharmaceutical companies understand biological
systems at a resolution and scale that matches the complexity of
biology. Our products are behind breakthroughs in oncology,
immunology, neuroscience and more, fueling powerful discoveries
that are transforming the world's understanding of health and
disease. To learn more, visit 10xgenomics.com or connect with us on
LinkedIn or X (Twitter).
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which are
subject to the "safe harbor" created by those sections. All
statements included in this press release, other than statements of
historical facts, may be forward-looking statements.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as "may," "might," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplate," "believe," "see," "estimate,"
"predict," "potential," "would," "likely," "seek" or "continue" or
the negatives of these terms or variations of them or similar
terminology, but the absence of these words does not mean that a
statement is not forward-looking. These forward-looking statements
include statements regarding 10x Genomics, Inc.'s expected
financial results. These statements are based on management's
current expectations, forecasts, beliefs, assumptions and
information currently available to management. Actual outcomes and
results could differ materially from these statements due to a
number of factors and such statements should not be relied upon as
representing 10x Genomics, Inc.'s views as of any date subsequent
to the date of this press release. 10x Genomics, Inc. disclaims any
obligation to update any forward-looking statements provided to
reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based,
except as required by law. The material risks and uncertainties
that could affect 10x Genomics, Inc.'s financial and operating
results and cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release include those discussed under the captions "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" in the company's most recently-filed
10-K and elsewhere in the documents 10x Genomics, Inc. files with
the Securities and Exchange Commission from time to time.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-preliminary-fourth-quarter-and-full-year-2023-results-302028127.html
SOURCE 10x Genomics, Inc.